Is Gilead Sciences' Stock a Bargain by the Numbers?

Before you go, we thought you'd like these...
Before you go close icon

Numbers can lie -- yet they're the best first step in determining whether a stock is a buy. In this series, we use some carefully chosen metrics to size up a stock's true value based on the following clues:

  • The current price multiples.
  • The consistency of past earnings and cash flow.
  • How much growth we can expect.

Let's see what those numbers can tell us about how expensive or cheap Gilead Sciences (NAS: GILD) might be.

The current price multiples
First, we'll look at most investors' favorite metric: the P/E ratio. It divides the company's share price by its earnings per share (EPS) -- the lower, the better.

Then we'll take things up a notch with a more advanced metric: enterprise value to unlevered free cash flow, which divides the company's enterprise value (basically, its market cap plus its debt, minus its cash) by its unlevered free cash flow (its free cash flow, adding back the interest payments on its debt). As with the P/E, the lower this number is, the better.

Analysts argue about which is more important -- earnings or cash flow. Who cares? A good buy ideally has low multiples on both.

Gilead has a P/E ratio of 10.6 and an EV/FCF ratio of 9.2 over the trailing 12 months. If we stretch and compare current valuations with the five-year averages for earnings and free cash flow, we see that Gilead has a P/E ratio of 15.3 and a five-year EV/FCF ratio of 12.3.

A positive one-year ratio of less than 10 for both metrics is ideal (at least in my opinion). For a five-year metric, less than 20 is ideal.

Gilead has a mixed performance in hitting the ideal targets, but let's see how it stacks up against some of its competitors and industry mates. 

Company

1-Year P/E

1-Year EV/FCF

5-Year P/E

5-Year EV/FCF

Gilead Sciences10.69.215.312.3
Bristol-Myers Squibb (NYS: BMY) 16.811.611.816.4
Merck (NYS: MRK) 25.59.817.916.8
Teva Pharmaceutical (NAS: TEVA) 11.914.117.016.3

Source: S&P Capital IQ; NM = not meaningful because of losses.

Numerically, we've seen how Gilead's valuation rates on both an absolute and relative basis. Next, let's examine ...

The consistency of past earnings and cash flow
An ideal company will be consistently strong in its earnings and cash-flow generation.

In the past five years, Gilead's net income margin has ranged from -11.2% to 38.5%. In that same time frame, unlevered free cash flow margin has ranged from 38.2% to 41.1%.

How do those figures compare with those of the company's peers? See for yourself:

anImage

Source: S&P Capital IQ; margin ranges are combined.

Source: S&P Capital IQ; margin ranges are combined.

In addition, over the past five years, Gilead has tallied up four years of positive earnings and five years of positive free cash flow.

Next, let's figure out ...

How much growth we can expect

Analysts tend to comically overstate their five-year growth estimates. If you accept them at face value, you willoverpay for stocks. But even though you should definitely take the analysts' prognostications with a grain of salt, they can still provide a useful starting point when compared with similar numbers from a company's closest rivals.

Let's start by seeing what this company's done over the past five years. In that time period, Gilead has put up past EPS growth rates of 34.3%. Meanwhile, Wall Street's analysts expect future growth rates of 15.6%.

Here's how Gilead compares with its peers for trailing-five-year growth:

anImage

Source: S&P Capital IQ; EPS growth shown.

Source: S&P Capital IQ; EPS growth shown.

And here's how it measures up with regard to the growth analysts expect over the next five years:

anImage

Source: S&P Capital IQ; estimates for EPS growth.

Source: S&P Capital IQ; estimates for EPS growth.

The bottom line
The pile of numbers we've plowed through has shown us the price multiples that shares of Gilead are trading at, the volatility of its operational performance, and what kind of growth profile it has -- both on an absolute and a relative basis.

The more consistent a company's performance has been and the more growth we can expect, the more we should be willing to pay. We've gone well beyond looking at a 10.6 P/E ratio, and we see that all of its price multiples are in the reasonable-to-cheap range. And except for one year of losses, its profitability and margins have been solid. Its earnings are better now versus five years ago as well.

One thing to watch out for is that free cash flows don't account for the significant cash acquisitions Gilead has made.

Overall, our CAPS community is impressed enough to rate Gilead five stars out of five. But this is just a start. If you find Gilead Sciences' numbers or story compelling, don't stop here. Continue your due-diligence process until you're confident one way or the other. As a start, add it to My Watchlist to find all of our Foolish analysis.

You can also see the stocks that I've researched beyond the initial numbers and bought in my public real-money portfolio.

At the time this article was published Anand Chokkaveluand The Motley Fool own shares of Teva Pharmaceutical Industries.Motley Fool newsletter serviceshave recommended buying shares of Teva Pharmaceutical Industries and Gilead Sciences. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners